Clinical trial

ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab

NCT05082259

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2022-03-02

PhasePHASE1

Study timeline

Study start (actual)2022-03-02Date precision: day

Registry last updated2026-06-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Cancerunresolved

Cervical Cancerunresolved

Triple Negative Breast Cancerunresolved

Interventions

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Sponsors & collaborators

Institute of Cancer Research, United Kingdomlead sponsor

Astex Pharmaceuticals, Inc.collaborator

Merck Sharp & Dohme LLCcollaborator

Cancer Research UKcollaborator

Mapped research locations

CambridgeUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05082259 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.